Abu Dhabi Advances Gene Editing Therapies Targeting Rare Diseases Through Strategic Global Collaboration

• Partnership supports the next phase of the Emirate’s ambition to translate genomic insights into advanced therapies, clinical research and future manufacturing capabilities

Abu Dhabi, UAE – 25 June 2026: Building on the Emirate’s growing leadership in genomics, precision medicine and preventive population health, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, M42, a global health leader, and Mammoth Biosciences have signed a Memorandum of Understanding (MoU) at the BIO International Convention 2026 in San Diego to advance gene-editing therapies, develop clinical research and advance therapy manufacturing in Abu Dhabi.